wherein Grifols agreed to exclusively manufacture and supply plasma-derived products for use in the biosurgery field for 10 years. In 2021, Grifols announced the acquisition of Tiancheng (Germany ...

The takeover deliberations come shortly after Grifols completed the sale of its 20% stake in Chinese blood products unit Shanghai RAAS to Haier, a deal first announced in 2020, raising cash of ...

Grifols’ share price previously fell more than 40% in January after the short-seller Gotham posted a report on January 9 claiming the Spanish blood-plasma products maker had manipulated its ...

Grifols is anticipating a period of strong ... as well as a new bi-weekly dosing approval for Xembify and pipeline products fibrinogen and trimodulin. The drugmaker has been involved in a series ...

Drugmaker Grifols SA and US short seller Gotham City Research are counting on two different reports from a Spanish regulator to bolster their cases as they prepare to face off in court.

Grifols, a global healthcare company and leading producer of plasma-derived medicines, today announced it has received a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF ...

The future results of the Grifols group could be affected by events relating to its own activities, such as a shortage of supplies of raw materials for the manufacture of its products, the ...

The Catalan blood products company has received a $21 million grant from the Michael J. Fox Foundation (MJFF) for Parkinson's ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

Grifols has more than 24,000 employees in 30 countries and regions, and its products are sold in more than 100 countries through four divisions: bioscience, diagnostic, hospital and bio supplies. The ...

The unique plasma assets serve as the foundation of the Chronos-PD program, driving advanced research at Grifols subsidiary Alkahest, which is leading the initiative given its specialization in the ...